Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout
Abstract Gout is caused by elevated serum urate levels, which can be treated using inhibitors of the uric acid transporter, URAT1. Here, we characterize verinurad (RDEA3170), which is currently under evaluation for gout therapy. Verinurad specifically inhibits URAT1 with a potency of 25 nM. High aff...
Guardado en:
Autores principales: | Philip K. Tan, Sha Liu, Esmir Gunic, Jeffrey N. Miner |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/101d72a4c0c246b6a3c62d73d187ccad |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The ABCG2 Q141K hyperuricemia and gout associated variant illuminates the physiology of human urate excretion
por: Kazi Mirajul Hoque, et al.
Publicado: (2020) -
Management of hyperuricemia in gout: focus on febuxostat
por: Mattheus K Reinders, et al.
Publicado: (2010) -
Behavioral Characteristics of Gout Patients and Their Impact on the Results of Urate Lowering Therapy
por: J. Chen, et al.
Publicado: (2021) -
Atypical musculoskeletal manifestations of gout in hyperuricemia patients
por: Sakti M, et al.
Publicado: (2019) -
Replication of Gout/Urate Concentrations GWAS Susceptibility Loci Associated with Gout in a Han Chinese Population
por: Zhiqiang Li, et al.
Publicado: (2017)